Over the last decades several randomized and observational studies have reported a
significant improvement in biochemical control favouring combined treatments over
EBRT alone. Nonetheless, prostate brachytherapy is still performed only in highly
specialised centres and EBRT is still widely considered the standard of care in radiotherapy
for prostate cancer. This might be partly explained by the toxicity profile reported
in the aforementioned studies. The objective of this study is to describe the genitourinary
(GU) and gastrointestinal (GI) late toxicity profile and to analyse the clinical and
dosimetric predictive factors in a prospective trial of combination of EBRT and high-dose-rate
(HDR) prostate brachytherapy (BT) for prostate cancer.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to BrachytherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
PSOR04Presentation Time: 11:45 AM
